mrna

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

7 days ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates…

2 months ago

Erin M. Schuman Wins 2026 Nakasone Award for Discovery on Neural Synapse Function and Change During Formation of Memories

STRASBOURG, France, July 9, 2025 /PRNewswire/ -- The International Human Frontier Science Program Organization (HFSPO) is pleased to award the…

3 months ago